knowledge -WSS

knowledge

author：focus 2025-09-30 20:18:48 - browse：1798

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Trump demands the U.S. pay no more for drugs than other countries … again
Next article： Parkland mass shooting to be reenacted for lawsuit

Wikipedia

focus

WSS

The battle over the Brookhaven Landfill on Long Island

Paxlovid study fails to answer questions over benefit for broader groups

WATCH: Why do fingernails fall off when they're damaged?

Death of patient in Alzheimer’s trial raises question of possible risks

Cloning humans is technically possible. It's curious no one has tried

Calls for Trump's election interference trial to be televised part of long debate

focus

knowledge

knowledge

Novavax promises a turnaround & Lilly roils the obesity market

Why are elite athletes different? Take a look at their microbes

Medical leaders decry Supreme Court decision on affirmative action

New guidelines on severe brain injury complicate already difficult decisions

Hepatitis C has a cure — but many Americans still lack access to it

Rock icon Freddie Mercury pre

Jerome Adams on the need for new antivirals for Covid

FDA grants conditional OK to Sarepta’s gene therapy for Duchenne

Apple is now the first public company to be valued at $3 trillion

Scientists find bacteria from stomach of ancient iceman

focus

The strategy behind pharma's lawsuits over drug pricing reform

Tuesday set an unofficial record for the hottest day on Earth. Wednesday may break it.

Weight bias in eating disorder treatment complicated by new weight loss drugs

Colonoscopy at 40? Study finds a possible benefit

Medical mystery: When an infection after surgery isn’t what it seems

Death of patient in Alzheimer’s trial raises question of possible risks

Wikipedia

focus

focus

entertainment